Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials
What you need to know
The weekly injectable GLP-1 receptor agonist semaglutide is approved for use in type 2 diabetes at a dose optimized for glucose lowering, of 1.0 mg/week. But the results of the first STEP trial show that at a higher dose of 2.4 mg/week it is also an effective weight loss agent, easily surpassing the effects of any currently available medication.
Browse this page for details of the completed and ongoing STEP trials, and the SELECT cardiovascular outcomes study, plus interviews with the researchers.
Stay informed with Medicine Matters
Get the latest developments in diabetes delivered straight to your inbox